المؤلفون: Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio. Electronic address: dimad@ccf.org., Li H; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Hansen D; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Sidana S; Stanford University School of Medicine, Stanford, California., Shune L; University of Kansas Medical Center, Kansas City, Kansas., Anwer F; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Sborov D; University of Utah Huntsman Cancer Institute, Salt Lake City, Utah., Wagner C; University of Utah Huntsman Cancer Institute, Salt Lake City, Utah., Kocoglu MH; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland., Atrash S; Levine Cancer Institute, Charlotte, North Carolina., Voorhees P; Levine Cancer Institute, Charlotte, North Carolina., Peres L; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Hovanky V; Stanford University School of Medicine, Stanford, California., Simmons G; Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia., Williams L; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Raza S; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Afrough A; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas., Anderson LD Jr; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas., Ferreri C; The University of Texas MD Anderson Cancer Center, Houston, Texas., Hashmi H; Medical University of South Carolina, Charleston, South Carolina., Davis J; Medical University of South Carolina, Charleston, South Carolina., McGuirk J; University of Kansas Medical Center, Kansas City, Kansas., Goldsmith S; City of Hope Cancer Center, Duarte, California., Borogovac A; City of Hope Cancer Center, Duarte, California., Lin Y; Mayo Clinic Cancer Center, Rochester, Minnesota., Midha S; Dana-Farber Cancer Institute, Boston, Massachusetts., Nadeem O; Dana-Farber Cancer Institute, Boston, Massachusetts., Locke FL; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Baz R; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Hamilton B; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Alsina M; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Sauter C; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Patel K; The University of Texas MD Anderson Cancer Center, Houston, Texas., Kaur G; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas.

المصدر: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Aug; Vol. 30 (8), pp. 790.e1-790.e16. Date of Electronic Publication: 2024 Jun 02.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/mortality , Multiple Myeloma*/immunology, Humans ; Middle Aged ; Male ; Female ; Aged ; Lymphocyte Count ; Retrospective Studies ; Treatment Outcome ; Tissue Extracts/therapeutic use ; Cancer Vaccines/therapeutic use ; United States/epidemiology ; Immunotherapy/methods ; Receptors, Chimeric Antigen

المؤلفون: Lin Y; Department of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: lin.yi@mayo.edu., Qiu L; National Clinical Research Center for Blood Diseases and State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Pekin Union Medical College, Tianjin, China., Usmani S; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Joo CW; Department of Medical Oncology, National University Cancer Institute, Singapore., Costa L; Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA., Derman B; Department of Hematology and Oncology, University of Chicago, Chicago, IL, USA., Du J; Department of Hematology, Myeloma and Lymphoma Center, Shanghai Changzheng Hospital, Navy Medical University, Shanghai, China., Einsele H; Department of Internal Medicine II, University Hospital, Wurzburg, Germany., Fernandez de Larrea C; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Hajek R; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Hematooncology, Faculty of Medicine, University Ostrava, Ostrava, Czech Republic., Ho PJ; Institute of Hematology, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia., Kastritis E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Martinez-Lopez J; Hospital Universitario 12 de Octubre, Department of Medicine, Complutense University, CNIO, Madrid, Spain., Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain., Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA., Moreau P; Department of Hematology, University Hospital of Nantes, Nantes, France., Nagarajan C; Department of Haematology, Singapore General Hospital, Singapore., Nooka A; Winship Cancer Institute of Emory University, Atlanta, GA, USA., O'Dwyer M; Department of Medicine and Department of Haematology, National University of Ireland, Galway, Ireland., Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway., Sidana S; School of Medicine, Stanford University, San Francisco, CA, USA., van de Donk NW; Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Zweegman S; Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Raje N; Department of Medicine, Harvard University, Cambridge, MA, USA., Otero PR; Department of Hematology, Cancer Center Clinica Universidad de Navarra, Pamplona, Navarra, Spain., Anderson LD Jr; Simmons Comprehensive Cancer Center, Dallas, TX, USA; University of Texas Southwestern Medical Center, Dallas, TX, USA., Kumar S; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Martin T; Department of Hematology, University of California, San Francisco, CA, USA.

مؤلفون مشاركون: International Myeloma Working Group

المصدر: The Lancet. Oncology [Lancet Oncol] 2024 Aug; Vol. 25 (8), pp. e374-e387. Date of Electronic Publication: 2024 May 28.

نوع المنشور: Journal Article; Review; Practice Guideline

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/immunology , Immunotherapy, Adoptive*/adverse effects , Receptors, Chimeric Antigen*/immunology , Receptors, Chimeric Antigen*/therapeutic use , Consensus*, Humans ; Treatment Outcome ; Receptors, Antigen, T-Cell/therapeutic use ; Receptors, Antigen, T-Cell/immunology

المؤلفون: Chari A; Icahn School of Medicine at Mount Sinai, New York, NY, USA. ajai.chari@ucsf.edu., Kaufman JL; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Laubach J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Sborov DW; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA., Reeves B; University of North Carolina-Department of Medicine-Chapel Hill, Chapel Hill, NC, USA., Rodriguez C; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Silbermann R; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Costa LJ; University of Alabama at Birmingham, Birmingham, AL, USA., Anderson LD Jr; Myeloma, Waldenstrӧm's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Nathwani N; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Shah N; University of California San Francisco, San Francisco, CA, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Holstein SA; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Costello C; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Jakubowiak A; University of Chicago Medical Center, Chicago, IL, USA., Wildes TM; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cowan AJ; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA., Pei H; Janssen Research & Development, LLC, Titusville, NJ, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Voorhees PM; Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA. Peter.Voorhees@atriumhealth.org., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org., Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

المصدر: Blood cancer journal [Blood Cancer J] 2024 Jul 08; Vol. 14 (1), pp. 107. Date of Electronic Publication: 2024 Jul 08.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/mortality , Multiple Myeloma*/therapy , Multiple Myeloma*/diagnosis , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Aged ; Female ; Male ; Middle Aged ; Adult ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use ; Bortezomib/therapeutic use ; Bortezomib/administration & dosage ; Lenalidomide/therapeutic use ; Lenalidomide/administration & dosage

المؤلفون: Dima D; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.; University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Goel U; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA., Sannareddy A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Ibeh N; Department of Pathology and Laboratory Medicine, University of Texas, Houston, Texas, USA., Ullah F; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA., Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Mazzoni S; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Mehdi A; Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio, USA., Rudoni J; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Raza S; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., De Simone N; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Williams L; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Khan A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Rashid A; Department of Internal Medicine, University of Kansas, Kansas City, Kansas, USA., Rice M; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Ricci K; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Samaras C; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Valent J; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Anwer F; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA., Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Khouri J; Multiple Myeloma Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.

المصدر: Hematological oncology [Hematol Oncol] 2024 Jul; Vol. 42 (4), pp. e3293.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 8307268 Publication Model: Print Cited Medium: Internet ISSN: 1099-1069 (Electronic) Linking ISSN: 02780232 NLM ISO Abbreviation: Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/mortality , Plasma Exchange*/methods, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Treatment Outcome ; Adult ; Aged, 80 and over ; Kidney Diseases/therapy ; Kidney Diseases/etiology

المؤلفون: Silbermann R; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA., Laubach J; Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA., Kaufman JL; Department of Mematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Sborov DW; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA., Reeves B; Division of Hematology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA., Rodriguez C; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA., Chari A; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA., Costa LJ; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Anderson LD Jr; Division of Hematology/Oncology, Simmons Comprehensive Cancer Center, UT Texas Southwestern Medical Center, Dallas, Texas, USA., Nathwani N; Division of Myeloma, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Shah N; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA., Holstein SA; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA., Costello C; Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, California, USA., Jakubowiak A; Medicine- Hematology and Oncology, University of Chicago, Chicago, Illinois, USA., Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Cowan AJ; Department of Medicine, University of Washington, Seattle, Washington, USA., Gries KS; Janssen Research & Development, Raritan, New Jersey, USA., Pei H; Janssen Research & Development, LLC, Titusville, New Jersey, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Voorhees PM; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA., Usmani SZ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Richardson PG; Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA.

المصدر: American journal of hematology [Am J Hematol] 2024 Jul; Vol. 99 (7), pp. 1257-1268. Date of Electronic Publication: 2024 Apr 15.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Quality of Life* , Bortezomib*/administration & dosage , Bortezomib*/therapeutic use , Dexamethasone*/administration & dosage , Dexamethasone*/therapeutic use , Lenalidomide*/administration & dosage , Lenalidomide*/therapeutic use , Patient Reported Outcome Measures* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult

المؤلفون: Zanwar S; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA., Sidana S; Stanford University School of Medicine, Stanford, CA, USA., Shune L; The University of Kansas Medical Center, Kansas City, KS, USA., Puglianini OC; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Pasvolsky O; Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gonzalez R; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Afrough A; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Kaur G; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Davis JA; Medical University of South Carolina, Charleston, SC, USA., Herr M; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Hashmi H; Medical University of South Carolina, Charleston, SC, USA.; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Forsberg P; University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Sborov D; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Anderson LD Jr; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., McGuirk JP; The University of Kansas Medical Center, Kansas City, KS, USA., Wagner C; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Lieberman-Cribbin A; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Rossi A; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Freeman CL; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Locke FL; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Richard S; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Lin Y; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA., Patel KK; Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. KPatel1@mdanderson.org., Kumar SK; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. Kumar.Shaji@mayo.edu., Hansen DK; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Doris.Hansen@moffitt.org.

المصدر: Journal of hematology & oncology [J Hematol Oncol] 2024 Jun 06; Vol. 17 (1), pp. 42. Date of Electronic Publication: 2024 Jun 06.

نوع المنشور: Letter; Multicenter Study; Journal Article

بيانات الدورية: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Tissue Extracts/therapeutic use ; Treatment Outcome ; Biological Products/therapeutic use ; Retrospective Studies ; Immunotherapy, Adoptive/methods ; Progression-Free Survival ; Receptors, Chimeric Antigen

المؤلفون: Nooka AK; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Kaufman JL; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Rodriguez C; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Jakubowiak A; University of Chicago Medical Center, Chicago, Illinois, USA., Efebera Y; OhioHealth, Columbus, Ohio, USA., Reeves B; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Wildes TM; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Holstein SA; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Anderson LD Jr; Myeloma, Waldenström's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Badros A; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland, USA., Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Chari A; Icahn School of Medicine at Mount Sinai, New York, New York, USA.; University of California at San Francisco, San Francisco, California, USA., Pei H; Janssen Research & Development, LLC, Titusville, New Jersey, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Voorhees PM; Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, North Carolina, USA., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Richardson PG; Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA.

المصدر: British journal of haematology [Br J Haematol] 2024 Jun; Vol. 204 (6), pp. 2227-2232. Date of Electronic Publication: 2024 Mar 19.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Lenalidomide*/administration & dosage , Lenalidomide*/adverse effects , Lenalidomide*/therapeutic use , Dexamethasone*/administration & dosage , Dexamethasone*/adverse effects , Dexamethasone*/therapeutic use , Bortezomib*/administration & dosage , Bortezomib*/adverse effects , Bortezomib*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Multiple Myeloma*/drug therapy , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/adverse effects , Antibodies, Monoclonal*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Black or African American

المؤلفون: Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Abraham PR; Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Turer L; Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Sannareddy A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Hansen DK; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.

المصدر: Acta haematologica [Acta Haematol] 2024 May 08, pp. 1-15. Date of Electronic Publication: 2024 May 08.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Karger Country of Publication: Switzerland NLM ID: 0141053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9662 (Electronic) Linking ISSN: 00015792 NLM ISO Abbreviation: Acta Haematol Subsets: MEDLINE

المؤلفون: Hashmi H; Medical University of South Carolina., Hansen DK; H. Lee Moffitt Cancer Center and Research Institute., Peres LC; H. Lee Moffitt Cancer Center and Research Institute., Puglianini OC; H. Lee Moffitt Cancer Center and Research Institute., Freeman C; H. Lee Moffitt Cancer Center and Research Institute., De Avila G; H. Lee Moffitt Cancer Center and Research Institute., Sidana S; Stanford University School of Medicine., Shune L; The University of Kansas Medical Center., Sborov DW; The University of Utah Huntsman Cancer Institute., Davis J; Medical University of South Carolina., Wagner C; The University of Utah Huntsman Cancer Institute., Kocoglu MH; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center., Atrash S; Levine Cancer Institute., Voorhees P; Levine Cancer Institute., Simmons G; Virginia Commonwealth University Massey Cancer Center., Ferreri C; The University of Texas MD Anderson Cancer Center., Kalariya N; The University of Texas MD Anderson Cancer Center., Anderson LD Jr; UT Southwestern Harold C. Simmons Comprehensive Cancer Center., Afrough A; UT Southwestern Harold C. Simmons Comprehensive Cancer Center., Dima D; Cleveland Clinic, Cleveland, OH., Khouri J; Cleveland Clinic, Cleveland, OH., McGuirk J; The University of Kansas Medical Center., Locke F; H. Lee Moffitt Cancer Center and Research Institute., Baz R; H. Lee Moffitt Cancer Center and Research Institute., Patel KK; The University of Texas MD Anderson Cancer Center., Alsina M; H. Lee Moffitt Cancer Center and Research Institute.

المصدر: Haematologica [Haematologica] 2024 May 01; Vol. 109 (5), pp. 1514-1524. Date of Electronic Publication: 2024 May 01.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Multicenter Study

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/immunology , Multiple Myeloma*/mortality , Immunotherapy, Adoptive*/methods , Immunotherapy, Adoptive*/adverse effects , Disease Progression*, Humans ; Male ; Female ; Middle Aged ; Aged ; Biological Products/therapeutic use ; Biological Products/administration & dosage ; Adult ; B-Cell Maturation Antigen/immunology ; Antigens, CD19/immunology ; Antigens, CD19/therapeutic use ; Recurrence ; Treatment Outcome ; Aged, 80 and over ; Drug Resistance, Neoplasm ; United States/epidemiology ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/therapeutic use ; Receptors, Chimeric Antigen/immunology ; Receptors, Chimeric Antigen/therapeutic use ; Risk Factors

المؤلفون: Hydren JR; HealthTree Foundation, Lehi, UT, United States., Lin D; Janssen Scientific Affairs, LLC, Horsham, PA, United States., Sweeney NW; HealthTree Foundation, Lehi, UT, United States., Wu B; Janssen Scientific Affairs, LLC, Horsham, PA, United States., Kim N; Janssen Scientific Affairs, LLC, Horsham, PA, United States., Patel S; Janssen US Oncology Medical Affairs, Horsham, PA, United States., Sborov DW; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States., Berdeja JG; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, United States., Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States., Huo S; Janssen Scientific Affairs, LLC, Horsham, PA, United States., Hurtado Martínez JA; HealthTree Foundation, Lehi, UT, United States., Ahlstrom JM; HealthTree Foundation, Lehi, UT, United States.

المصدر: Frontiers in health services [Front Health Serv] 2024 Apr 24; Vol. 4, pp. 1354760. Date of Electronic Publication: 2024 Apr 24 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 9918334887706676 Publication Model: eCollection Cited Medium: Internet ISSN: 2813-0146 (Electronic) Linking ISSN: 28130146 NLM ISO Abbreviation: Front Health Serv Subsets: PubMed not MEDLINE